Philips and Masimo partner to advance access to patient monitoring technologies
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
Philips and Masimo will also collaborate on the development and co-promotion of next-generation monitoring solutions
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
CRISPR-based detection enables highly specific molecular recognition
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Subscribe To Our Newsletter & Stay Updated